Apolizumab
From Wikipedia, the free encyclopedia
Apolizumab?
|
|
Therapeutic monoclonal antibody | |
Source | Human |
Target | 1D10 |
Identifiers | |
CAS number | ? |
ATC code | ? |
PubChem | ? |
Chemical data | |
Formula | ? |
Mol. mass | ? |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.[1]
[edit] References
- ^ Bayes M, Rabasseda X, Prous J (2003). "Gateways to clinical trials.". Methods Find Exp Clin Pharmacol 25 (9): 747–71. PMID 14685303.
|